These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7897163)

  • 21. Mononuclear cells from patients with the hyper-IgE syndrome produce little IgE when they are stimulated with recombinant human interleukin-4.
    Claasen JJ; Levine AD; Schiff SE; Buckley RH
    J Allergy Clin Immunol; 1991 Nov; 88(5):713-21. PubMed ID: 1720150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of high doses of intravenous gamma-globulin on platelet interaction with the vessel wall in Kawasaki disease.
    Inagaki M; Yamada K
    Acta Paediatr Jpn; 1991 Dec; 33(6):791-8. PubMed ID: 1801559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of in vitro antibody synthesis with the outcome of intravenous gamma-globulin treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel J; Pahwa S; Porges A; Cunningham-Rundles S; Koziner B; Morell A; Barandun S
    J Clin Immunol; 1986 Jan; 6(1):50-6. PubMed ID: 2420817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kawasaki disease in infants less than one year of age.
    Rosenfeld EA; Corydon KE; Shulman ST
    J Pediatr; 1995 Apr; 126(4):524-9. PubMed ID: 7699529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atopic dermatitis or hyper-IgE syndrome?
    Ohameje NU; Loveless JW; Saini SS
    Allergy Asthma Proc; 2006; 27(3):289-91. PubMed ID: 16913276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M; Ohki H; Tsuchihashi T; Yamagishi H; Katada Y; Yamada K; Yamashita Y; Sugaya A; Komiyama O; Shiro H
    Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-4 and interferon-gamma production in children with atopic disease.
    Tang M; Kemp A; Varigos G
    Clin Exp Immunol; 1993 Apr; 92(1):120-4. PubMed ID: 8467557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of IgE production by anti-CD40 antibody in atopic dermatitis.
    Renz H; Brodie C; Bradley K; Leung DY; Gelfand EW
    J Allergy Clin Immunol; 1994 Mar; 93(3):658-68. PubMed ID: 7512104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome.
    Sogkas G; Hirsch S; Jablonka A; Witte T; Schmidt RE; Atschekzei F
    Clin Immunol; 2020 Jun; 215():108452. PubMed ID: 32360519
    [No Abstract]   [Full Text] [Related]  

  • 30. Overview of pharmacological treatment of Kawasaki disease.
    Onouchi Z; Kawasaki T
    Drugs; 1999 Nov; 58(5):813-22. PubMed ID: 10595862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen presenting cell-independent cytokine and spontaneous in vitro IgE production in patients with atopic dermatitis: increased interferon-gamma production and lack of effects of in vivo low-dose interferon-gamma treatment.
    Simon MR; Cooper KD; Norris RB; Blok B; King CL
    J Allergy Clin Immunol; 1995 Jul; 96(1):84-91. PubMed ID: 7622767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab.
    Nihal A; Comstock JR; Holland KE; Singh AM; Seroogy CM; Arkin LM
    Pediatr Dermatol; 2022 Nov; 39(6):940-942. PubMed ID: 35734823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased prevalence of atopic dermatitis in Kawasaki disease.
    Brosius CL; Newburger JW; Burns JC; Hojnowski-Diaz P; Zierler S; Leung DY
    Pediatr Infect Dis J; 1988 Dec; 7(12):863-6. PubMed ID: 3211629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.
    Muta H; Ishii M; Furui J; Nakamura Y; Matsuishi T
    Acta Paediatr; 2006 Feb; 95(2):189-93. PubMed ID: 16449025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomolecular regulation of the IgE immune response. II. In vitro IgE synthesis and spontaneous production of cytokines.
    Poulsen LK; Reimert CM; Bindslev-Jensen C; Hansen MB; Bendtzen K
    Int Arch Allergy Immunol; 1995 Jan; 106(1):55-61. PubMed ID: 7812167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine imbalance in hyper-IgE syndrome: reduced expression of transforming growth factor beta and interferon gamma genes in circulating activated T cells.
    Ohga S; Nomura A; Ihara K; Takahata Y; Suga N; Akeda H; Shibata R; Okamura J; Kinukawa N; Hara T
    Br J Haematol; 2003 Apr; 121(2):324-31. PubMed ID: 12694256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iv gamma globulin treatment of Kawasaki disease in Japan: results of a nationwide survey.
    Yanagawa H; Yashiro M; Nakamura Y; Sakata K; Kawasaki T
    Acta Paediatr; 1995 Jul; 84(7):765-8. PubMed ID: 7549294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of interferon-gamma and interleukin-4 on IgE production in B lymphocytes of patients with atopic dermatitis. A possible criterion for selection of patients for interferon therapy.
    Gruner S; Liebenthal C; Heusser C; Brinkmann V; Zwirner A; Reinicke C; Harnack K; Sönnichsen N; Volk HD
    Acta Derm Venereol; 1991; 71(6):484-7. PubMed ID: 1685830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis.
    Hiratsuka S; Yoshida A; Ishioka C; Kimata H
    J Allergy Clin Immunol; 1996 Jul; 98(1):107-13. PubMed ID: 8765824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome.
    Kimata H; Fujimoto M; Furusho K
    Eur J Immunol; 1995 Jun; 25(6):1497-501. PubMed ID: 7614976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.